A multicenter randomized phase II study published in BMC Cancer demonstrated that nab-paclitaxel combined with cisplatin outperforms gemcitabine monotherapy in treating advanced biliary tract cancer. This regimen showed improved efficacy and safety profiles in this patient population, potentially redefining standard chemotherapy options. These data support further development of combination treatments to improve outcomes in biliary malignancies with historically poor prognoses.